En undersøgelse for at teste, om BI 771716 hjælper mennesker med en avanceret form for aldersrelateret makuladegeneration (AMD) kaldet geografisk atrofi (VERDANT)
Randomiseret, dobbeltmaskeret, AKTIVT KONTROLLERET, multicenterundersøgelse for at evaluere effektiviteten og sikkerheden af to regimer af Intravitreal BI 771716 mod Pegcetacoplan hos deltagere med geografisk atrofi sekundært til aldersrelateret makuladegeneration VERDANT-forsøg
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.
In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.
Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, Forenede Stater, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, Forenede Stater, 85050
- Phoenix Retina Associates
-
Scottsdale, Arizona, Forenede Stater, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Glendale, California, Forenede Stater, 91204
- Global Research Management
-
Huntington Beach, California, Forenede Stater, 92647
- Retina Associates of Southern California
-
Modesto, California, Forenede Stater, 95356
- Retinal Consultants Medical Group, Inc
-
Newport Beach, California, Forenede Stater, 92663
- Eye Research Foundation
-
Poway, California, Forenede Stater, 92064
- Retina Consultants of San Diego
-
Sacramento, California, Forenede Stater, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, Forenede Stater, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Lakewood, Colorado, Forenede Stater, 80228
- Colorado Retina Associates
-
-
Connecticut
-
Danbury, Connecticut, Forenede Stater, 06810
- Connecticut Eye Consultants, PC
-
Waterford, Connecticut, Forenede Stater, 06385
- Retina Group of New England, PC
-
-
Florida
-
Deerfield Beach, Florida, Forenede Stater, 33064
- Rand Eye Institute
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- Retina Group of Florida
-
Pinellas Park, Florida, Forenede Stater, 33782
- Eye Associates of Pinellas
-
St. Petersburg, Florida, Forenede Stater, 33711
- Retina Vitreous Associates of Florida
-
-
Georgia
-
Augusta, Georgia, Forenede Stater, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Lemont, Illinois, Forenede Stater, 60439
- University Retina and Macula Associates
-
Oak Park, Illinois, Forenede Stater, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40206
- Butchertown Clinical Trials
-
-
Maryland
-
Hagerstown, Maryland, Forenede Stater, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Ophthalmic Consultants of Boston
-
-
Minnesota
-
Edina, Minnesota, Forenede Stater, 55435
- Retina Consultants of Minnesota
-
-
Mississippi
-
Madison, Mississippi, Forenede Stater, 39110
- Mississippi Retina Associates
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65212
- University of Missouri Health System
-
-
New Jersey
-
Bloomfield, New Jersey, Forenede Stater, 07003
- Envision Ocular, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- Eye Associates of New Mexico
-
-
New York
-
Westbury, New York, Forenede Stater, 11590
- Long Island Vitreoretinal Consultants - Westbury
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forenede Stater, 18017
- Mid Atlantic Retina - Bethlehem
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, Forenede Stater, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, Forenede Stater, 77707
- Retina Consultants of Texas - Beaumont
-
Bellaire, Texas, Forenede Stater, 77401
- Retina Consultants of Texas-Bellaire-67493
-
Dallas, Texas, Forenede Stater, 75231
- Retina Foundation of the Southwest
-
Katy, Texas, Forenede Stater, 77494
- Retina Consultants of Texas - Katy
-
Plano, Texas, Forenede Stater, 75024
- Red River Research Partners, LLC
-
San Antonio, Texas, Forenede Stater, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, Forenede Stater, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, Forenede Stater, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84107
- Retina Associates of Utah
-
-
Virginia
-
Lynchburg, Virginia, Forenede Stater, 24502
- Piedmont Eye Center
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99204
- Spokane Eye Clinic
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria
-
Age at least 50 years old at the time of randomization visit
-
Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
-
Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use are provided in the participant information. Male participants must be ready and able to use either a condom or abstinence as contraceptive measures
-
Diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), where the total GA lesion area must be ≥2.5 square millimetres (mm²) and ≤17.5 mm² as measured by Fundus autofluorescence (FAF)
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥1.25 mm²
- Note: Fellow eye is not required to have GA
- Note: subfoveal GA lesions (defined as GA lesions within 1 micron of the foveal center point) will be allowed to be enrolled until a maximum of approximately 60% of participants with subfoveal GA lesions are enrolled. Participants with subfoveal GA lesions already in screening at the time the cap has been reached may be considered for randomization.
-
Fellow eye must have sufficient visual function compared to the study eye, per the investigator's medical judgment in consultation with the patient, to support the patient's daily functioning
-
BCVA letter score of ≥24 letters, using the ETDRS chart in the study eye (equivalent to ≥20/320 on the Snellen chart). Note: If both eyes meet eligibility criteria, the eye with the worse visual function per the investigator's medical judgment in consultation with the patient, will be selected as the study eye. If both eyes have similar visual function, the study eye will be selected per the investigator's medical judgment in consultation with the patient
-
further inclusion criteria apply
Exclusion criteria
-
GA lesions whose area cannot be accurately defined in the study eye
-
Exudative neovascular AMD (eAMD) in the study eye
-- Note: eAMD in the fellow eye is allowed. However, if the fellow eye is to be considered for microperimetry and other analyses (as defined in the trial statistical analysis plan), then eAMD is not allowed in either eye.
-
Previously received treatment in the study eye for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer
-
Previously received an investigational medication (oral or intravitreal) for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer
-
Currently enrolled in another investigational device or drug trial, or 30 days or 5 half-lives, whichever is longer since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Any previous use of gene therapy or cell therapy is not permitted
-
Additional eye disease as follows:
- Any eye disease in the study eye that could compromise BCVA
- Uncontrolled glaucoma or ocular hypertension with intraocular pressure >24 millimetre of mercury (mmHg) in study eye
- History of high myopia >8 diopters in the study eye
- Anterior segment and vitreous abnormalities that would preclude adequate observation with spectral domain optical coherence tomography in the study eye
- Ocular conditions at the discretion of the investigator that might interfere with outcome of the trial in the study eye
- Active intraocular inflammation in the study eye
- Active infectious conjunctivitis in either eye
-
Prior vitrectomy surgery in the study eye
-
History of major intraocular surgeries including major corneal surgery. Uneventful cataract surgery, refractive surgery, oculoplastic surgery, strabismus surgery, and other extraocular surgery may be permitted if they have occurred more than 3 months prior to baseline in the study eye
-
further exclusion criteria apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm A: BI 771716
|
BI 771716 |
|
Eksperimentel: Arm B: BI 771716 og Sham komparator
|
BI 771716 Sham comparator to BI 771716 |
|
Aktiv komparator: Arm C: Pegcetacoplan
|
Pegcetacoplan
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Hældning af ændring fra baseline i kvadratrodstransformeret geografisk atrofi (GA) område målt ved fundus autofluorescens (FAF) i undersøgelsesøjet udtrykt i millimeter (mm)/år
Tidsramme: Ved baseline i uge 56
|
Ved baseline i uge 56
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i kvadratrodstransformeret GA-areal målt ved FAF i undersøgelsesøjet udtrykt i mm
Tidsramme: Ved baseline i uge 56
|
Ved baseline i uge 56
|
|
Ændring fra baseline i den bedste korrigerede synsskarphed (BCVA) målt ved hjælp af standardiserede tidlige forsøgsdiabetisk retinopatiundersøgelse (ETDRS) diagram i undersøgelsens øje
Tidsramme: Ved baseline i uge 56
|
Ved baseline i uge 56
|
|
Forekomst af BCVA-brevtab på ≥15 bogstaver målt ved standardiseret ETDRS-diagram i undersøgelsesøjet i mindst 2 på hinanden følgende besøg
Tidsramme: Op til uge 56
|
Op til uge 56
|
|
Forekomst af eksudativ neovaskulær aldersrelateret makuladegeneration (eAMD) i undersøgelsesøjet fra første lægemiddeladministration indtil uge 56
Tidsramme: Op til uge 56
|
Op til uge 56
|
|
Forekomst af lægemiddelrelaterede bivirkninger (AE) fra første lægemiddeladministration til uge 56
Tidsramme: Op til uge 56
|
Op til uge 56
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 1497-0002
- U1111-1308-7923 (Registry Identifier: WHO International Clinical Trials Registry Platform (ICTRP))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD-delingstidsramme
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD-delingsadgangskriterier
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .